31 January 2024 in Cancer Research
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease that lacks effective treatment options, highlighting the need for developing new therapeutic interventions. Here, we assessed the response to pharmacologic inhibition of KRAS, the central oncogenic driver of PDAC. In a panel of PDAC cell lines, inhibition of KRASG12D with MRTX1133 yielded variable efficacy in suppressing cell growth and downstream gene expression programs in 2D cultures. On the basis of CRISPR-Cas9 loss-of-function screens, ITGB1 was identified as a target to enhance the therapeutic response to MRTX1133 by regulating mechanotransduction signaling and YAP/TAZ expression, which was confirmed by gene-specific knockdown and combinatorial drug synergy. Interestingly, MRTX1133 was considerably more efficacious in 3D cell cultures. Moreover, MRTX1133 elicited a pronounced cytostatic effect in vivo and controlled tumor growth in PDAC patient-derived xenografts. In syngeneic models, KRASG12D inhibition led to tumor regression that did not occur in immune-deficient hosts. Digital spatial profiling on tumor tissues indicated that MRTX1133-mediated KRAS inhibition enhanced IFNγ signaling and induced antigen presentation that modulated the tumor microenvironment. Further investigation of the immunologic response using single-cell sequencing and multispectral imaging revealed that tumor regression was associated with suppression of neutrophils and influx of effector CD8+ T cells. Together, these findings demonstrate that both tumor cell-intrinsic and -extrinsic events contribute to response to MRTX1133 and credential KRASG12D inhibition as a promising therapeutic strategy for a large percentage of patients with PDAC. Significance: Pharmacologic inhibition of KRAS elicits varied responses in pancreatic cancer 2D cell lines, 3D organoid cultures, and xenografts, underscoring the importance of mechanotransduction and the tumor microenvironment in regulating therapeutic responses.
29 October 2026 in Molecular Cancer Therapeutics
Multiple myeloma (MM), the second most common hematologic malignancy, remains incurable despite major therapeutic advances, highlighting an urgent need for novel therapeutic strategies. PCNA is involved in DNA replication and repair, chromatin remodeling, and cell-cycle progression, and increased PCNA expression has been associated with aggressive MM phenotypes and poor clinical outcomes. Cancer cells express a post-translationally modified cancer-associated isoform of PCNA (caPCNA), potentially providing a selective therapeutic target. We evaluated the anti-myeloma activity of the novel caPCNA inhibitor AOH1996 alone and in combination with established anti-myeloma agents in vitro, in vivo, and ex vivo. AOH1996 inhibited growth of multiple MM cell lines in a dose-dependent manner, induced G2-phase accumulation and apoptosis, and reduced sphere formation and colony formation capacity. Combination treatment with bortezomib, venetoclax, melphalan, or cyclophosphamide enhanced anti-myeloma activity relative to single-agent treatment. AOH1996 treatment down-regulated the expression of multiple tumor-associated proteins and inflammatory and pro-survival cytokines. miRNA analysis demonstrated suppression of several oncogenic miRNAs along with upregulation of tumor-suppressive miRNA miR-145. Forced expression of miR-145 inhibited MM cell growth and enhanced sensitivity to AOH1996, implicating miR-145 as a mechanistic mediator of PCNA inhibition’s anti-tumor effects. In xenograft models, AOH1996 significantly enhanced the anti-tumor activity of bortezomib and venetoclax without apparent toxicity. Ex vivo studies demonstrated selective activity against primary MM cells and CD138+ plasma cells with minimal effects on normal PBMCs. Collectively, these findings support caPCNA as a promising therapeutic target in MM and provide strong preclinical rationale for further clinical investigation of AOH1996-based therapeutic strategies.